Stradefy Biosciences

Stradefy Biosciences

Bioadhesive drug carriers for oncology and immunology.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round

N/A

Spinout
Total Funding000k
Notes (0)
More about Stradefy Biosciences
Made with AI
Edit

Based in New Haven, Connecticut, Stradefy Biosciences is a private drug discovery and development company pioneering bioadhesive drug carriers (BDCs). The company's technology is an advancement from its initial work on a nanoparticle-based sunscreen and therapeutic platform. The firm's core mission is to engineer these next-generation BDCs for enhanced cellular bioadhesion, uptake, and therapeutic payload release, aiming for levels that exceed those of antibody-drug conjugates (ADCs). This is designed to maximize the effectiveness of active drug products by improving retention and internalization in target cells and tissues, thereby reducing systemic toxicities.

Stradefy Biosciences was co-founded by Mark Saltzman, Michael Girardi, Yale University, and Elm Street Ventures. The company's foundation is built upon research conducted by Saltzman and Girardi at Yale, for which it holds strong patent protection. In December 2023, Jeffrey M. Goldberg, an executive with over 25 years in the biotechnology sector, was appointed as Executive Chair. Goldberg has experience leading companies like Aeglea Biotherapeutics and Immunitas Therapeutics through preclinical discovery to commercialization.

The company's business model is centered on developing its proprietary BDC technology to create new immunotherapies. The primary focus is on addressing unmet needs in oncology and immunology. Its lead candidates have already shown proof of efficacy in multiple in-vivo oncology models and are progressing toward the Investigational New Drug (IND) stage. The business strategy follows a capital-efficient path to achieve proof of concept in targeted oncology applications. Stradefy Biosciences serves pharmaceutical companies by providing a platform to create more effective treatments for diseases like cancer.

Keywords: bioadhesive drug carriers, BDCs, drug delivery, oncology, immunology, nanoparticles, antibody-drug conjugates, cellular bioadhesion, therapeutic payload release, targeted therapy, immunotherapy, Yale spin-out, preclinical, IND stage, cancer treatment, autoimmune diseases, drug development, biotherapeutics, life sciences, nanotechnology

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads